NCT00109122View on ClinicalTrials.gov

Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

February 28, 2003

Study Completion Date

July 31, 2006

Conditions
Shingles
Interventions
BIOLOGICAL

zoster vaccine live (Oka/Merck)

BIOLOGICAL

Comparator: placebo (unspecified)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00109122 - Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) | Biotech Hunter | Biotech Hunter